Sell-Side Analysts Including Deutsche and Barclays Feel Bullish About These 15 Stocks

Sell-Side Analysts Including Deutsche and Barclays Feel Bullish About These 15 Stocks

Research  these Stocks on Kapitall’s Playground Now

 
research now

A Sell-Side Analyst works for a brokerage to compose reports and forecast the markets for their clients.  They’ll typically focus on a specific industry and produce regular reports containing predictions on commodity prices and expected performance for a stock.

Main Street investors benefit from sell-side analyst reports since seasoned experts typically the ones to write them. Better yet, sell-side research as a whole outperforms that of buy-side, which is a important considering the analyst and the firm’s reputation can stand on the line with each “buy,” “sell” or “hold” rating.

But be warned, every report produced by a sell-side analyst is called a “blanket recommendation” because they do not take into account the wants and needs of every individual. Investors must therefore determine if they are applicable to their own portfolio.

And don’t forget, the analyst is paid by the brokerage, not the clients themselves, the report could be part of an agenda of the firm that you don’t know about.  So remember to measure twice and cut once because their reports do not necessarily provide proper advice for an individual investor.

Business Section: Investing Ideas

Before considering the recommendations made by sell-side analysts, just remember that this is not private knowledge.  Information spreads fast on the Internet, and their optimism could already be priced in.

We gathered the sell-side analyst ratings from reputable firms including Argus, Barclays, Canaccord Genuity, Collins Stewart, and Deutsche.

We then screened for the stocks that had “Buy”, “Outperform”, or “Overweight” ratings from at least two of those names. 15 stocks made the cut. We list them below.

 

1. Aegerion Pharmaceuticals, Inc. (AEGR, Earnings, Analysts, Financials): Engages in the development and commercialization of novel therapeutics to treat severe lipid disorders. Market cap at $307.8M, most recent closing price at $14.72. Canaccord Genuity and Deutsche Bank.

 

2. Allergan Inc. (AGN, Earnings, Analysts, Financials): Operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Market cap at $28.18B, most recent closing price at $91.64. Argus and Deutsche Bank.

 

3. The Allstate Corporation (ALL, Earnings, Analysts, Financials): Engages in the personal property and casualty insurance, life insurance, retirement, and investment products businesses primarily in the United States. Market cap at $16.92B, most recent closing price at $34.44. Argus and Deutsche Bank.

 

4. Alexion Pharmaceuticals, Inc. (ALXN, Earnings, Analysts, Financials): Engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Market cap at $17.86B, most recent closing price at $92.96. Barclays and Canaccord Genuity.

 

5. American Tower Corporation (AMT, Earnings, Analysts, Financials): Operates as a wireless and broadcast communications infrastructure company. Market cap at $26.52B, most recent closing price at $67.20. Barclays and Canaccord Genuity.

 

6. Anthera Pharmaceuticals, Inc. (ANTH, Earnings, Analysts, Financials): Focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Market cap at $91.61M, most recent closing price at $2.23. Collins Stewart and Deutsche.

 

7. Biogen Idec Inc. (BIIB, Earnings, Analysts, Financials): Develops, manufactures, and markets therapeutics in the areas of neurology, immunology, hemophilia, and oncology in the United States and internationally. Market cap at $33.22B, most recent closing price at $138.66. Deutsche and Barclays.

 

8. BioMarin Pharmaceutical Inc. (BMRN, Earnings, Analysts, Financials): Develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Market cap at $4.49B, most recent closing price at $36.77. Canaccord Genuity and Deutsche Bank.

 

9. Broadcom Corp. (BRCM, Earnings, Analysts, Financials): Designs and develops semiconductors for wired and wireless communications. Market cap at $18.67B, most recent closing price at $33.89. Canaccord Genuity and Deutsche Bank.

 

10. The Blackstone Group (BX, Earnings, Analysts, Financials): Provides alternative asset management and financial advisory services worldwide. Market cap at $13.88B, most recent closing price at $12.29. Argus and Deutsche Bank.

 

11. CONSOL Energy Inc. (CNX, Earnings, Analysts, Financials): Engages in the production of multi-fuel energy and provision of energy services primarily to the electric power generation industry in the United States. Market cap at $6.28B, most recent closing price at $27.58. Barclays and Deutsche Bank.

 

12. ECA Marcellus Trust I (ECT, Earnings, Analysts, Financials): Holds royalty interests in producing and development horizontal natural gas wells for Energy Corporation of America (ECA). Market cap at $305.89M, most recent closing price at $17.37. Barclays and Deutsche Bank.

 

13. Equity Residential (EQR, Earnings, Analysts, Financials): Engages in the acquisition, development, and management of multifamily properties in the United States. Market cap at $18.99B, most recent closing price at $61.92. Argus and Barclays.

 

14. Corporate Executive Board Co. (EXBD, Earnings, Analysts, Financials): Provides business insights, data, and tools to business executives and professionals in the United States, Europe, and internationally. Market cap at $1.29B, most recent closing price at $38.39. Barclays and Deutsche Bank.

 

15. HCA Holdings, Inc. (HCA, Earnings, Analysts, Financials): Offers health care services in the United States. Market cap at $11.58B, most recent closing price at $26.40. Barclays and Deutsche Bank.

 

 

Written by Ryan Horch. Data sourced from Reuters and Finviz.

 

Use Kapitall’s Tools: Looking for ways to analyze this list?

Use this article snapshot as a launch pad (click here for help): Simply click on the links, and use Kapitall’s tab navigation to browse through the data…

 

Analyze These Ideas: Getting Started

Dig Deeper: Access Company Snapshots, Charts, Filings

New to Kapitall?

1. New to the site? Click here to register for a free account, and gain access to more tools and data
2. Looking for more investing ideas like this? Click here to sign up for your free copy of Kapitall Weekly
3. Follow us on SeekingAlpha, Motley Fool, Nasdaq and Twitter

 

 

ABOUT KAPITALL WIRE

Kapitall Wire, which is not a broker/dealer, offers free cutting edge investing ideas, lively commentary and timely analysis of companies enhanced by interactive tools. And the Investing 101 section breaks complex concepts down to their basics, offering education to novices that doubles as a refresher course for more seasoned investors.

Kapitall Wire is a division of Kapitall Inc. Securities products and services are offered by Kapitall Generation, LLC, member FINRA/SIPC . Kapitall Generation, LLC is a wholly owned subsidiary of Kapitall, Inc.

If you can drag you can drop you can trade. Start by 3/31/2012, to trade for $5 for life

Join now

One Response to “Sell-Side Analysts Including Deutsche and Barclays Feel Bullish About These 15 Stocks”

  1. Kaycee Karlinsky says:

    I just could not go away your web site before suggesting that I very enjoyed the usual info a person supply to your guests? Is going to be back ceaselessly to be able to inspect new posts. 836826

Leave a Reply

Protected by WP Anti Spam

If you can drag you can drop you can trade. Start by 3/31/2012, to trade for $5 for life

Join now

http://wire.kapitall.com/wp-content/themes/kapitall/img/Banners/TOLT_1.jpg

Thanks For Signing Up!